Home
Resources
Diseases
COVID-19
Ebola
Hepatitis B
Human papillomavirus (HPV)
Malaria
Measles
Mpox
Pneumococcal disease
RSV (Respiratory syncytial virus)
Compendium
Hepatitis B birth dose vaccines
Hexavalent vaccines
HPV vaccines
Malaria vaccines
Measles containing vaccines
PCV vaccines
RSV vaccines
Typhoid Conjugate Vaccines
Training
Vaccine Portfolio Optimization and Prioritization (VPOP)
Evaluation
The Tool
The Tutorial
The Dashboard
SYSVAC
About
Registry
E-learning courses
News
Webinars
Network
Steering Committee
Vision and Mission
Map
Meetings
Partners
Join us
Home
Resources
Resources
Selected
Mpox
Type of publications
Guidelines (2)
NITAG documentation (22)
SAGE documentation (7)
Systematic reviews (SYSVAC) (28)
Regions
Africa (1)
Americas (7)
Europe (12)
Western Pacific (3)
Diseases
Mpox (59)
Chikungunya (13)
Cholera (35)
COVID-19 (1599)
Cytomegalovirus (1)
Dengue (45)
Diphtheria (92)
Ebola (21)
Escherichia coli (ETEC) (2)
Haemophilus influenzae type B (72)
Hepatitis A (71)
Hepatitis B (175)
Hepatitis C (5)
Hepatitis E (5)
Herpes simplex (1)
Herpes zoster (81)
HIV / AIDS (10)
Human papillomavirus (HPV) (545)
Influenza (639)
Japanese encephalitis (35)
Lyme disease, Borreliosis (2)
Malaria (35)
Measles (148)
Meningococcal disease (157)
Moraxella catarrhalis (1)
Mumps (53)
Pertussis (122)
Pneumococcal disease (310)
Poliomyelitis (98)
Q fever (1)
Rabies (33)
Rotavirus (122)
RSV (Respiratory syncytial virus) (71)
Rubella (72)
Salmonella (3)
Shigella (1)
Smallpox (16)
Streptococcus group B (6)
Tetanus (73)
Tick-borne encephalitis (14)
Tuberculosis (84)
Typhoid (33)
Varicella (79)
Yellow fever (45)
Zika (1)
Show more
Methodological quality (AMSTAR 2)
Moderate (1)
Low (7)
Critically low (6)
Not applicable (14)
59 results found
2024
Updated recommendations for mpox vaccination in Spain
2024
∙
ATAGI
ATAGI Clinical Guidance on the use of vaccines for the prevention of Mpox
2024
Updated recommendations for vaccination against mpox in Spain
2024
∙
ATAGI
ATAGI interim statement on the use of vaccines for prevention of mpox in 2024
2024
∙
NACI
Interim guidance on the use of Imvamune® in the context of a routine immunization program
2023
∙
Moawad, M. H. Taha, A. M. Nguyen, D. Ali, M. Mohammed, Y. A. Moawad, W. A. E. Hamouda, E. Bonilla-Aldana, D. K. Rodriguez-Morales, A. J.
Attitudes towards Receiving Monkeypox Vaccination: A Systematic Review and Meta-Analysis
2023
∙
Akter, F. Hasan, T. B. Alam, F. Das, A. Afrin, S. Maisha, S. Masud, A. A. Saif-Ur-Rahman, K. M.
Effect of prior immunisation with smallpox vaccine for protection against human monkeypox: A systematic review
2023
∙
Nave, L. Margalit, I. Tau, N. Cohen, I. Yelin, D. Lienert, F. Yahav, D.
Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine-A Systematic Review and Meta-Analysis of Randomized Controlled Trials
2023
∙
Xu, M. Liu, C. Du, Z. Bai, Y. Wang, Z. Gao, C.
Real-world effectiveness of monkeypox vaccines: A systematic review
2023
∙
Malone, Shelia M. Mitra, Amal K. Onumah, Nwanne A. Brown, Alexis Jones, Lena M. Tresvant, Da'Chirion Brown, Cagney S. Onyia, Austine U. Iseguede, Faith O.
Safety and Efficacy of Post-Eradication Smallpox Vaccine as an Mpox Vaccine: A Systematic Review with Meta-Analysis
Home
Resources
Diseases
Compendium
Training
Evaluation
SYSVAC
News
Webinars
Network
Sign in / Register